april 22 semaglutide On February 21, 2025, the FDA announced that semaglutide, the active ingredient in Ozempic and Wegovy, is no longer considered in shortage, signaling an improvement in national supply. As a result, compounding Drug compounders sue FDA over

Your card ID may stay the same, but you'll need to re-accept the updated 2026 terms

Clinical trials have reported a higher incidence of gastrointestinal adverse events, including duodenal ulceration, compared to other antidiabetic agents 65

We know when we manage our patients with type 2 diabetes, we not only need to be concerned about glycemic control, but also about reducing cardiometabolic risk as well as weight reduction since most of our patients are overweight or obese, Juan P

Clinical evaluations indicate that Chlorogenic Acid modulates glucose metabolism and fatty acid oxidation, supporting healthy weight maintenance through mechanisms distinct from incretin pathways

This table illustrates a clear progression